Get the Stockscreener App
8.28
2.93%
-0.25
Arcus Biosciences Inc stock is traded at $8.28, with a volume of 1.19M.
It is down -2.93% in the last 24 hours and up +4.28% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$8.53
Open:
$8.46
24h Volume:
1.19M
Relative Volume:
1.01
Market Cap:
$965.67M
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-2.6796
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
-9.21%
1M Performance:
+4.28%
6M Performance:
-53.61%
1Y Performance:
-48.73%
1-Day Range:
$8.26
$8.875
1-Week Range:
$7.06
$9.10
52-Week Range:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
8.28 | 965.67M | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
Arcus Biosciences (RCUS): Morgan Stanley Lowers Price Target | R - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Stock Titan
Morgan Stanley Lowers Price Target on Arcus Biosciences to $22 From $24, Keeps Overweight Rating - marketscreener.com
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) | RCUS Stock News - GuruFocus
Arcus Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Arcus Biosciences (RCUS) Receives Adjusted Price Target from Wel - GuruFocus
Analyzing Ratios: Arcus Biosciences Inc (RCUS)’s Financial Story Unveiled - DWinneX
European regulators to review Valneva shot; Jazz's stock dips on subpar first-quarter revenue - Endpoints News
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) to $26 | RCUS Stock News - GuruFocus
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2025 Earnings Call Transcript - MSN
Arcus Biosciences (RCUS) Receives Adjusted Price Target from Wells Fargo | RCUS Stock News - GuruFocus
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Arcus Biosciences Q1 2025 Earnings Call Transcript - MarketBeat
Arcus Biosciences Inc (RCUS) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo Finance
Arcus Biosciences earnings missed by $0.12, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Arcus Biosciences Q1 2025 misses earnings estimates - Investing.com
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings call transcript: Arcus Biosciences Q1 2025 misses earnings estimates By Investing.com - Investing.com India
Arcus Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Arcus Biosciences (RCUS) Misses Q1 Revenue Expectations, Outlines Future Plans | RCUS Stock News - GuruFocus
Arcus Biosciences Q1 2025 Earnings: EPS Misses at -$1.14, Revenue Falls Short at $28 Million - GuruFocus
Arcus Biosciences Q2 2025 slides: advancing late-stage oncology pipeline with $1B cash - Investing.com Canada
Arcus Cancer Drug Shows Breakthrough 30% Response Rate in Kidney Cancer Trial, Reports Strong Q1 Earnings - Stock Titan
Earnings To Watch: Arcus Biosciences Inc (RCUS) Reports Q1 2025 Result - GuruFocus
Renaissance Technologies LLC Lowers Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Bounce 33% But Its Business Still Trails The Industry - simplywall.st
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Long Term Trading Analysis for (RCUS) - news.stocktradersdaily.com
Wells Fargo & Company MN Has $575,000 Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Taking the lead: Arcus Biosciences Inc (RCUS) - Sete News
Arcus Biosciences Inc (RCUS) Stock: Navigating a Year of Volatility - investchronicle.com
Can you now get a good deal on Arcus Biosciences Inc’s shares? - uspostnews.com
Arcus Biosciences Inc [RCUS] Investment Guide: What You Need to Know - knoxdaily.com
Arcus Biosciences Inc (NYSE: RCUS) Could Soar To Much Higher Prices In Coming Months - Marketing Sentinel
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Invesco Ltd. - Defense World
Barclays Cuts Arcus Biosciences (NYSE:RCUS) Price Target to $14.00 - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News - GuruFocus
RCUSArcus Bioscience Latest Stock News & Market Updates - Stock Titan
Are Arcus Biosciences Inc (RCUS) shares a good deal now? - uspostnews.com
Russell Investments Group Ltd. Raises Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences to Present First Combination Data for HIF-2a I - GuruFocus
Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting | RCUS Stock News - GuruFocus
Groundbreaking Kidney Cancer Treatment Data: Arcus Reveals First Casdatifan-Cabozantinib Results at ASCO 2025 - Stock Titan
Arcus Biosciences Inc (RCUS) Is A Buy According To Analysts - Marketing Sentinel
Forecasting The Future: 5 Analyst Projections For Arcus Biosciences - Benzinga
Arcus Biosciences (RCUS) Price Target Slashed by Barclays to $14 - GuruFocus
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update | RCUS Stock News - GuruFocus
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update - Business Wire
Arcus Biosciences to Host Conference Call to Discuss First-Quart - GuruFocus
Geode Capital Management LLC Decreases Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):